Evidence map›Paper›PMID 41901316›Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

From Environmental Risk to Cancer Stemness: Epigenetic Regulation in Oral Squamous Cell Carcinoma.

Milica Jaksic Karisik, Katarina Zeljic, Jelena Carkic, Milos Lazarevic, Giuseppe Damante, Stefan Mitic, Jelena Milasin

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Milica Jaksic KarisikSchool of Dental Medicine, University of Belgrade, Dr. Subotica 8, 11000 Belgrade, Serbia.ORCID 0000-0003-1114-0829
Katarina ZeljicFaculty of Biology, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-6545-8616
Jelena CarkicSchool of Dental Medicine, University of Belgrade, Dr. Subotica 8, 11000 Belgrade, Serbia.ORCID 0000-0002-1014-7589
Milos LazarevicSchool of Dental Medicine, University of Belgrade, Dr. Subotica 8, 11000 Belgrade, Serbia.ORCID 0000-0003-1330-5332
Giuseppe DamanteDepartment of Medical Area, University of Udine, 33100 Udine, Italy.
Stefan MiticClinic for Surgery, Clinical Hospital Centre "Dragisa Misovic-Dedinje", 11000 Belgrade, Serbia.ORCID 0009-0003-9275-4685
Jelena MilasinSchool of Dental Medicine, University of Belgrade, Dr. Subotica 8, 11000 Belgrade, Serbia.ORCID 0000-0002-6225-7210

Funding

Science Fund of the Republic of Serbia 7750038
6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) represents a major global health burden and remains one of the most prevalent and aggressive malignancies of the head and neck region. Despite significant advances in surgical techniques, chemotherapy, and radiotherapy, patient outcomes have improved only modestly over recent decades. The high recurrence rate, metastatic potential, and resistance to therapy underscore the complexity of OSCC biology and the limitations of conventional treatment approaches. In recent years, the concept of cancer stem cells (CSCs) has reshaped the understanding of tumor initiation, progression, and therapeutic failure in OSCC. These cells, characterized by self-renewal capacity and phenotypic plasticity, are believed to sustain tumor growth, drive recurrence, and mediate resistance to therapy. Parallel to this, insights into epigenetic regulation, including DNA methylation, histone modifications, and non-coding RNAs, have revealed new layers of molecular heterogeneity and adaptability in oral carcinogenesis. The integration of CSC biology with epigenetic modulation offers a promising foundation for the development of targeted and personalized therapeutic strategies. Novel approaches aim to eradicate CSCs, induce their differentiation, or reprogram their malignant phenotype through the use of epigenetic inhibitors and molecular modulators. This review summarizes current knowledge on the molecular and cellular mechanisms driving OSCC pathogenesis, highlights the emerging role of CSCs and epigenetic regulators, and discusses the challenges and perspectives of translating these findings into effective clinical therapies.

Indexed as

cancer stem cellsepigenetic modulationhistone modificationsmicroRNAsoral squamous cell carcinomaOSCC etiologytargeted therapy

Identifiers

PMID41901316
PMCPMC13029695

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.